quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:05:00·52d
PRRelease
Seres Therapeutics Inc. logo

Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates

MCRB· Seres Therapeutics Inc.
Health Care
Original source

Companies

  • MCRB
    Seres Therapeutics Inc.
    Health Care

Recent analyst ratings

  • May 8UpdateChardan Capital Markets$6.00
  • Oct 24UpdateJP Morgan-
  • Jun 26UpdateOppenheimer$12.00
  • Apr 21UpdateJP Morgan$7.00
  • Jul 23UpdateCanaccord Genuity$29.00
  • Jul 23UpdateChardan Capital$16.00

Related

  • PR4d
    Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
  • PR15d
    Seres Therapeutics to Present at CARB-X Investor Day
  • SEC38d
    SEC Form 8-K filed by Seres Therapeutics Inc.
  • SEC43d
    SEC Form 10-K filed by Seres Therapeutics Inc.
  • SEC43d
    SEC Form 8-K filed by Seres Therapeutics Inc.
  • PR43d
    Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
  • INSIDER43d
    SEC Form 4 filed by Seres Therapeutics Inc.
  • INSIDER43d
    New insider Brady Kelly claimed ownership of 8,441 shares (SEC Form 3)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022